Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co EBIT Margin

The EBIT Margin (Operating Margin) of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Oct 29, 2026 is 22.28 %. In the previous year, EBIT Margin (Operating Margin) was 33.16 % — a change of -32.81% (lower).

EBIT Margin

22.28 %

YoY

-32.81%

Last updated:

EBIT Margin (Operating Margin) of Pacific Shuanglin Bio-pharmacy Co is 2025 22.28 % . EBIT Margin (Operating Margin) of Pacific Shuanglin Bio-pharmacy Co was 2024 33.16 % . It decreases by -32.81% lower compared to the previous year.

For Pacific Shuanglin Bio-pharmacy Co, the operating (EBIT) margin of 22.3% is down versus 23.4% a few years ago.

The Pacific Shuanglin Bio-pharmacy Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
13.66 CNY
Jan 1, 2019
20.84 CNY
Jan 1, 2020
20.98 CNY
Jan 1, 2021
23.35 CNY
Jan 1, 2022
27.58 CNY
Jan 1, 2023
29.85 CNY
Jan 1, 2024
33.16 CNY
Jan 1, 2025
22.28 CNY
The Pacific Shuanglin Bio-pharmacy Co EBIT Margin history
YEAREBIT MarginYoY
22.28 %-32.81%
33.16 %+11.08%
29.85 %+8.23%
27.58 %+18.12%
23.35 %+11.29%
20.98 %+0.66%
20.84 %+52.55%
13.66 %+11.97%
12.20 %-12.73%
13.98 %+2.39%
13.66 %-33.32%
20.48 %+16,520.70%
0.12 %-61.56%
0.32 %-0.42%
0.32 %+145.75%
0.13 %-399.46%
-0.04 %+67,987.34%
-0.00-99.87%
-0.05 %+790.92%
-0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

EBIT Margin (Operating Margin) of Pacific Shuanglin Bio-pharmacy Co is 22.28 % in 2025.

EBIT Margin (Operating Margin) of Pacific Shuanglin Bio-pharmacy Co changed from 33.16 % to 22.28 %, representing a -32.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Pacific Shuanglin Bio-pharmacy Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pacific Shuanglin Bio-pharmacy Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co